/C O R R E C T I O N -- Shire PLC/

Thursday, October 18, 2007 General News J E 4
, In the news release, "Shire Plc: ThirdQuarter 2007 Results Date Notification - 1 November 2007" issued on 17 Oct2007 11:00 GMT, by Shire PLC LSE:SHP over PR Newswire, we are advised by arepresentative of the company that readers should note the revised US releaseissue time and changes to the US conference call times, as originally issuedinadvertently. Complete, corrected release follows:

Shire PLC (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) the global specialtybiopharmaceutical company, will announce third quarter 2007 earnings onThursday 1 November 2007.

Live conference call for investors:

Matthew Emmens, Chief Executive Officer and Angus Russell, ChiefFinancial Officer will host the live conference call for investors at 14:30GMT/10:30 ET.

Please RSVP (T: +44(0)1256-894-160) for this conferencecall.


A replay of the presentation will be available for two weeks by phone andby webcast for one year. Details are as follows:

Shire's strategic goal is to become the leading specialtybiopharmaceutical company that focuses on meeting the needs of the specialistphysician. Shire focuses its business on attention deficit and hyperactivitydisorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) andrenal diseases. The structure is sufficiently flexible to allow Shire totarget new therapeutic areas to the extent opportunities arise throughacquisitions. Shire's in-licensing, merger and acquisition efforts arefocused on products in niche markets with strong intellectual propertyprotection either in the US or Europe. Shire believes that a carefullyselected portfolio of products with strategically aligned and relativelysmall-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: press release will be issued at: 12:00 GMT / 08:00 ET Investor meeting and conference call time: 14:30 GMT / 10:30 ET



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Pharmion Initiates Pivotal Phase 3 Study of Amrubi...
GeneNews relocates to new facility